Seasoned biotech executive with deep experience and proven track record in successfully leading rare disease companies through rapid growth and development Boston, Mass. and Oxford, UK (February 4th, 2021) – PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced…
RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also…
We are excited to announce that PepGen will be part of an international project focusing on the role of the brain in Duchenne and Becker muscular dystrophy. Further details on this project can be found in the press release below: The BIND project is the first project of…
A recent publication utilising the precursor technology that underpins PepGen’s platform has been awarded ‘Paper of the Month‘ by the Board of Directors and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society (OTS). In addition, this publication is currently under consideration for the OTS Paper of the…
PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners,…
On the 1st of February 2019, PepGen’s £1.6M Innovate UK grant officially commenced. The company will initially focus on platform validation studies in small and large in vivo models, with project management and intellectual property workpackages running parallel to this experimental work.
PepGen has been awarded a grant of £1.6 M from Innovate UK, the UK’s innovation agency. The company’s project, entitled ‘Application of a novel peptide delivery platform to nucleic acid therapeutics in degenerative and rare diseases’, will run for 20 months, and this funding will be instrumental in…
PepGen is the first tenant of the BioEscalator development in Oxford, having moved into new office and laboratory spaces at these premises on the 10th of September 2018. The BioEscalator was built to support early-stage life sciences companies in Oxford, and offers extensive shared facilities to tenants, including…
On 26th March 2018 PepGen, a biotech company focused on the peptide-mediated delivery of nucleic acids, was spun out from the University of Oxford (OU) and the Medical Research Council (MRC). The intellectual property underpinning PepGen’s technology platform was developed through a decade-long collaboration between Professor Matthew Wood…
